Neuphoria Therapeutics Inc. NEUP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
-16.04
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $15.6M | -$400,000 | — | — | $19.0M |
| 2024 | — | -$15.5M | — | — | $17.5M |
| 2023 | — | -$21.4M | — | — | $22.0M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -16.04 (distress)
- Working capital / assets 0.378
- Retained earnings / assets -6.238
- EBIT / assets -0.039
- Equity / liabilities 1.982
Source: SEC EDGAR filings · CIK 0001191070 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.